Genetic Factors and Pheochromocytomas in Neoplasia Type 2 (NEM2A-Pheo)
Genetic Modifying Factors and Pheochromocytomas in Multiple Endocrine Neoplasia Type 2
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Frederic Castinetti
- Phone Number: 33 0491384131
- Email: frederic.castinetti@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13354
- Recruiting
- APHM - Hôpital de la Conception
-
Contact:
- Frédéric Castinetti
- Email: frederic.castinetti@ap-hm.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient aged 18 years or older
- Male or female patient
- Patient followed in the investigating department for familial NEM2A C634R (multiple endocrine neoplasia type 2) with or without pheochromocytoma
- Patient affiliated to or benefiting from a social security scheme
- Patient having given his non-opposition to participate in this study
- Patient who has given his consent for the genetic analysis carried out in the framework of the study
- Patient able to understand the purpose of the study
Exclusion Criteria:
- Protected persons (articles L1121-5, L1121-6 and L121-8 of the Public Health Code): pregnant or breastfeeding women, persons deprived of their liberty, under guardianship or curator
- Patients unable to understand the purpose of the study and the information note
Study Plan
How is the study designed?
Design Details
- Observational Models: Family-Based
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Genetic profile
Time Frame: Month 0
|
whole-exome analysis between patients with and without pheochromocytoma
|
Month 0
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Francois CREMIEUX, APHM
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2020-65
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.